HCM
NBIX icon

Highbridge Capital Management’s Neurocrine Biosciences NBIX Stock Holding History

Highbridge Capital Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-6,300
Closed -$250K – 1570
2015
Q1 		$250K Buy
+6,300
New +$225K ﹤0.01% 1197

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Highbridge Capital Management's NBIX Position: Q3 2017 in Review

Highbridge Capital Management sold out of Neurocrine Biosciences (NBIX) in Q3 2017, closing a stake of 50,000 shares — an estimated $2.3M sold.

Highbridge Capital Management first reported a position in NBIX in Q4 2013 and held it in 8 quarters. The position peaked at $10.5M in Q2 2015. 223 funds tracked by Wall St. Rank hold NBIX as of Q3 2017.

  • Highbridge Capital Management reported no remaining Neurocrine Biosciences position as of Q3 2017 after selling out during the quarter.
  • Highbridge Capital Management sold 50,000 Neurocrine Biosciences shares in Q3 2017, an estimated $2.3M.
  • Highbridge Capital Management first reported a position in Neurocrine Biosciences in Q4 2013 and held it in 8 quarters.
  • Highbridge Capital Management's Neurocrine Biosciences position peaked at $10.5M in Q2 2015.
  • 223 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2017.

Based on Highbridge Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.